Clevudine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clevudine
Clevudine Formulae.png
Systematic (IUPAC) name
1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine- 2,4-dione
Clinical data
Legal status ?
Routes Oral
Identifiers
CAS number 69256-17-3 YesY
ATC code J05AF12 [1]
PubChem CID 73115
ChemSpider 65894 N
UNII IN51MVP5F1 N
KEGG D03537 YesY
ChEMBL CHEMBL458875 N
Chemical data
Formula C10H13FN2O5 
Mol. mass 260.219 g/mol
 N (what is this?)  (verify)

Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.

Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathy cases in patients. It's approval in South Korea was revoked following these findings.

It is a nucleoside analog.[2]

References[edit]

  1. ^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05. 
  2. ^ Lee HS, Chung YH, Lee K, et al. (May 2006). "A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B". Hepatology 43 (5): 982–8. doi:10.1002/hep.21166. PMID 16628625.